Biblio

Export 2657 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is S  [Clear All Filters]
Journal Article
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
C. B. Malpas, Saling, M. M., Velakoulis, D., Desmond, P., Hicks, R. J., Zetterberg, H., Blennow, K., and O'Brien, T. J., “Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.”, J Alzheimers Dis, vol. 62, no. 1, pp. 417-427, 2018.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
A. Rivero-Santana, Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L. - O., Sarría, A., and Serrano-Aguilar, P., “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
A. Rivero-Santana, Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L. - O., Sarría, A., and Serrano-Aguilar, P., “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
S. Abu-Rumeileh, Mometto, N., Bartoletti-Stella, A., Polischi, B., Oppi, F., Poda, R., Stanzani-Maserati, M., Cortelli, P., Liguori, R., Capellari, S., and Parchi, P., “Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.”, J Alzheimers Dis, vol. 66, no. 2, pp. 551-563, 2018.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
A. Arighi, Di Cristofori, A., Fenoglio, C., Borsa, S., D'Anca, M., Fumagalli, G. Giulio, Locatelli, M., Carrabba, G., Pietroboni, A. Margherita, Ghezzi, L., Carandini, T., Colombi, A., Scarioni, M., De Riz, M. Alessandra, Serpente, M., Rampini, P. Maria, Scarpini, E., and Galimberti, D., “Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?”, J Alzheimers Dis, vol. 69, no. 3, pp. 663-669, 2019.
A. Arighi, Di Cristofori, A., Fenoglio, C., Borsa, S., D'Anca, M., Fumagalli, G. Giulio, Locatelli, M., Carrabba, G., Pietroboni, A. Margherita, Ghezzi, L., Carandini, T., Colombi, A., Scarioni, M., De Riz, M. Alessandra, Serpente, M., Rampini, P. Maria, Scarpini, E., and Galimberti, D., “Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?”, J Alzheimers Dis, vol. 69, no. 3, pp. 663-669, 2019.
A. Arighi, Di Cristofori, A., Fenoglio, C., Borsa, S., D'Anca, M., Fumagalli, G. Giulio, Locatelli, M., Carrabba, G., Pietroboni, A. Margherita, Ghezzi, L., Carandini, T., Colombi, A., Scarioni, M., De Riz, M. Alessandra, Serpente, M., Rampini, P. Maria, Scarpini, E., and Galimberti, D., “Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?”, J Alzheimers Dis, vol. 69, no. 3, pp. 663-669, 2019.
N. P. Rocha, Toledo, A., Corgosinho, L. T. S., de Souza, L. C., Guimarães, H. C., Resende, E. P. F., Braz, N. F. T., Gomes, K. B., Silva, A. C. Simoes E., Caramelli, P., and Teixeira, A. L., “Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-β42 Burden in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1085-1090, 2018.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
M. Shams, Martola, J., Charidimou, A., Granberg, T., Ferreira, D., Westman, E., Wintermark, M., Iv, M., Larvie, M., Wiberg, M. Kristoffer, Kaijser, M., Forsgard, N., Zetterberg, H., Wahlund, L. - O., and Shams, S., “Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease.”, J Alzheimers Dis, vol. 78, no. 3, pp. 1229-1236, 2020.
M. Shams, Martola, J., Charidimou, A., Granberg, T., Ferreira, D., Westman, E., Wintermark, M., Iv, M., Larvie, M., Wiberg, M. Kristoffer, Kaijser, M., Forsgard, N., Zetterberg, H., Wahlund, L. - O., and Shams, S., “Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease.”, J Alzheimers Dis, vol. 78, no. 3, pp. 1229-1236, 2020.
S. Lista, Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., Santos, A. Melo Dos, Epelbaum, S., Lamari, F., Dubois, B., Nisticò, R., Floris, R., Garaci, F., and Hampel, H., “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
A. De Vos, Struyfs, H., Jacobs, D., Fransen, E., Klewansky, T., De Roeck, E., Robberecht, C., Van Broeckhoven, C., Duyckaerts, C., Engelborghs, S., and Vanmechelen, E., “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.
E. van den Berg, Nilsson, J., Kersten, I., Brinkmalm, G., de Kort, A. M., Klijn, C. J. M., Schreuder, F. H. B. M., Jäkel, L., Gobom, J., Portelius, E., Zetterberg, H., Brinkmalm, A., Blennow, K., H Kuiperij, B., and Verbeek, M. M., “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
A. Morrow, Panyard, D. J., Deming, Y. K., Jonaitis, E., Dong, R., Vasiljevic, E., Betthauser, T. J., Kollmorgen, G., Suridjan, I., Bayfield, A., Van Hulle, C. A., Zetterberg, H., Blennow, K., Carlsson, C. M., Asthana, S., Johnson, S. C., and Engelman, C. D., “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
J. Svensson, Blomqvist, M., Kettunen, P., Eckerström, C., Henricsson, M., Jonsson, M., Bjerke, M., Månsson, J. - E., and Wallin, A., “Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 82, no. 2, pp. 781-790, 2021.

Pages